Pricing Is Main Draw For Biosimilars In China Despite Regulatory Uncertainty
This article was originally published in PharmAsia News
Executive Summary
Despite no word from China’s health regulators on a clear biosimilar approval pathway, competition is brewing. Chinese domestic biologics firms are stepping up to put biosimilars of blockbusters Herceptin and MabThera in front of regulators.